Your browser doesn't support javascript.
loading
[Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
Zhang, Jia-Ying; Zhu, Lei; Yang, Hong-Kuan; Chen, Fang.
Afiliação
  • Zhang JY; First Clinical Medical College,Zhejiang Chinese Medicine University,Hangzhou 310053,China.
  • Zhu L; First Clinical Medical College,Zhejiang Chinese Medicine University,Hangzhou 310053,China.
  • Yang HK; First Clinical Medical College,Zhejiang Chinese Medicine University,Hangzhou 310053,China.
  • Chen F; Department of Lung Function,First Affiliated Hospital,Zhejiang Chinese Medicine University,Hangzhou 310006,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao ; 40(3): 411-414, 2018 Jun 28.
Article em Zh | MEDLINE | ID: mdl-29978802
The past few years have witnessed rapid advances in the immunotherapies for non-small-cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic vaccine against lung cancer independently developed by Cuba. It can exert its anti-tumor effect by forming epidermal growth factor (EGF) antibodies to block the binding of EGF to EGF receptor. So far stage both phases Ⅱ and Ⅲ trials have proved its effectiveness and long-term safety,and phases Ⅲ and Ⅳ trials are underway. A deeper understanding of the role of CIMAvax-EGF in NSCLC will accelerate the application of immunotherapy. This article summarizes the recent advances of CIMAvax-EGF R&D and its application in treating NSCLC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Vacinas Anticâncer / Fator de Crescimento Epidérmico / Neoplasias Pulmonares Limite: Humans Idioma: Zh Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Vacinas Anticâncer / Fator de Crescimento Epidérmico / Neoplasias Pulmonares Limite: Humans Idioma: Zh Ano de publicação: 2018 Tipo de documento: Article